|
End-of-day quote
Shenzhen S.E.
28/10/2026
|
5-day change | 1st Jan Change | ||
| 2.810 CNY | +0.72% |
|
-5.70% | -12.73% |
Company Valuation: Realcan Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 7,826 | 5,881 | 6,165 | 4,920 | 4,444 | 4,779 |
| Change | - | -24.86% | 4.83% | -20.19% | -9.67% | 7.54% |
| Enterprise Value (EV) 1 | 12,117 | 5,846 | 4,743 | 6,684 | 6,040 | 5,640 |
| Change | - | -51.75% | -18.87% | 40.92% | -9.64% | -6.63% |
| P/E | 24.9x | 43.7x | -3.32x | 242x | 217x | 322x |
| PBR | 1.05x | 0.78x | 1.14x | 0.9x | 0.81x | 0.89x |
| PEG | - | -0.8x | 0x | -2x | 146.48x | -11.9x |
| Capitalization / Revenue | 0.29x | 0.28x | 0.5x | 0.61x | 0.56x | 0.66x |
| EV / Revenue | 0.45x | 0.28x | 0.39x | 0.83x | 0.76x | 0.77x |
| EV / EBITDA | 7.21x | 5.33x | 36.2x | 70x | 31.4x | 25.5x |
| EV / EBIT | 8.64x | 7.19x | -43.6x | -79.3x | 196x | 78x |
| EV / FCF | -4.62x | 1.03x | 0.99x | -1.81x | -56.6x | 5.15x |
| FCF Yield | -21.7% | 97.1% | 101% | -55.3% | -1.77% | 19.4% |
| Dividend per Share 2 | 0.018 | 0.009 | - | 0.013 | 0.011 | 0.002 |
| Rate of return | 0.34% | 0.23% | - | 0.4% | 0.37% | 0.06% |
| EPS 2 | 0.21 | 0.09 | -1.242 | 0.0135 | 0.0137 | 0.01 |
| Distribution rate | 8.57% | 10% | - | 96.3% | 80.3% | 20% |
| Net sales 1 | 27,204 | 21,060 | 12,311 | 8,034 | 7,966 | 7,296 |
| EBITDA 1 | 1,680 | 1,097 | 131.2 | 95.5 | 192.3 | 221.5 |
| EBIT 1 | 1,402 | 813.4 | -108.7 | -84.27 | 30.76 | 72.26 |
| Net income 1 | 261.3 | 131.2 | -1,832 | 20.32 | 20.62 | 16.07 |
| Net Debt 1 | 4,290 | -34.82 | -1,422 | 1,764 | 1,595 | 860.3 |
| Reference price 2 | 5.230 | 3.930 | 4.120 | 3.270 | 2.970 | 3.220 |
| Nbr of stocks (in thousands) | 1,496,437 | 1,496,437 | 1,496,437 | 1,504,710 | 1,496,437 | 1,484,264 |
| Announcement Date | 3/30/21 A | 4/29/22 A | 4/28/23 A | 4/29/24 A | 4/23/25 A | 4/22/26 A |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 620M | ||
| 37.84x | 13.27x | 28.43x | 0.53% | 1,148B | ||
| 39.67x | 6.67x | 18.75x | 1.97% | 652B | ||
| 37.4x | 8.39x | 17.35x | 2.4% | 505B | ||
| 21.45x | 5.21x | 12.93x | 2.51% | 384B | ||
| 102.73x | 5.76x | 24.72x | 2.42% | 348B | ||
| 21.89x | 5.76x | 13.88x | 2.85% | 294B | ||
| 22.21x | 4.49x | 12.82x | 1.97% | 264B | ||
| 28.66x | 7.33x | 13.12x | 2.23% | 244B | ||
| -45.79x | 7.11x | 27.55x | 2.07% | 197B | ||
| Average | 29.56x | 7.11x | 18.84x | 2.11% | 403.78B | |
| Weighted average by Cap. | 35.29x | 8.40x | 20.64x | 1.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 002589 Stock
- Valuation Realcan Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
















